Back to results
US 7,611,845 B2Granted
Serum levels of HER2/neu as an indicator of clinical state and prognosis of prostate cancer
AssigneeSiemens Healthcare Diagnostics Inc.
InventorsSamir Taneja, Carol D. Cheli
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing prostate cancer, predicting disease progression of prostate cancer, prognosing the stage and state of prostate cancer, and identifying appropriate treatment indication for prostate cancer patients. Methods encompass determining the levels of HER-2/neu in fluid biological samples (e.g., blood and serum) from patients.
Claims5
A method of identifying a human patient suffering from androgen insensitive metastatic prostate cancer who has an increased risk of disease related death, comprising:
- (a) determining a level of shed human Her-2/neu protein in a blood or serum sample from the patient;
- (b) comparing said patient sample shed human Her-2/neu protein level to an average level of shed human Her-2/neu protein in comparable blood or serum samples of other human patients suffering from said cancer;
- and
- (c) if said patient sample shed human Her-2/neu protein level found in step(a) is increased relative to said average level of shed human Her-2/neu protein, concluding that the patient has an increased risk of disease related death relative to said other patients;
- and
- wherein said patient and said other patients have previously been treated with hormone therapy.
3 more elements
Dependencies are inferred from the claim text.